Ocular Therapeutix Inc (OCUL)
5.81
-0.36
(-5.83%)
USD |
NASDAQ |
May 06, 16:00
5.805
0.00 (0.00%)
Pre-Market: 20:00
Ocular Therapeutix Research and Development Expense (Quarterly): 16.20M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 16.20M |
| September 30, 2023 | 15.02M |
| June 30, 2023 | 15.09M |
| March 31, 2023 | 14.75M |
| December 31, 2022 | 13.54M |
| September 30, 2022 | 13.72M |
| June 30, 2022 | 13.10M |
| March 31, 2022 | 13.10M |
| December 31, 2021 | 12.58M |
| September 30, 2021 | 12.72M |
| June 30, 2021 | 13.86M |
| March 31, 2021 | 10.93M |
| December 31, 2020 | 7.624M |
| September 30, 2020 | 6.951M |
| June 30, 2020 | 8.021M |
| March 31, 2020 | 6.098M |
| December 31, 2019 | 10.12M |
| September 30, 2019 | 10.24M |
| June 30, 2019 | 9.414M |
| March 31, 2019 | 11.32M |
| December 31, 2018 | 10.26M |
| September 30, 2018 | 9.685M |
| Date | Value |
|---|---|
| June 30, 2018 | 8.745M |
| March 31, 2018 | 8.227M |
| December 31, 2017 | 7.908M |
| September 30, 2017 | 8.126M |
| June 30, 2017 | 8.117M |
| March 31, 2017 | 6.729M |
| December 31, 2016 | 7.328M |
| September 30, 2016 | 5.686M |
| June 30, 2016 | 6.978M |
| March 31, 2016 | 7.073M |
| December 31, 2015 | 6.886M |
| September 30, 2015 | 8.263M |
| June 30, 2015 | 6.743M |
| March 31, 2015 | 4.719M |
| December 31, 2014 | 5.148M |
| September 30, 2014 | 4.482M |
| June 30, 2014 | 4.292M |
| March 31, 2014 | 4.958M |
| December 31, 2013 | 2.842M |
| September 30, 2013 | 2.784M |
| June 30, 2013 | 2.404M |
| March 31, 2013 | 2.487M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.098M
Minimum
Mar 2020
16.20M
Maximum
Dec 2023
11.74M
Average
12.72M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.343B |
| Assertio Holdings Inc | 1.024M |
| CytomX Therapeutics Inc | 19.39M |
| EyePoint Pharmaceuticals Inc | 17.95M |
| Regeneron Pharmaceuticals Inc | 1.248B |